Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Breast (Edinburgh, Scotland)|August 20, 2011
Late lines of treatment benefit survival in metastatic breast cancer in current practice?E Planchat, C Abrial, E Thivat, et al.
Medical Oncology (Northwood, London, England)|August 20, 2005
Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancersC Abrial, M A Mouret-Reynier, S Amat, et al.
Cancer Investigation|October 21, 2011
Prognostic value of initial tumor parameters after metastatic relapseE Planchat, X Durando, C Abrial, et al.
Annals of Surgical Oncology|March 4, 2008
Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentationP Gimbergues, C Abrial, X Durando, et al.
Annals of Surgical Oncology|May 2, 2009
Clinicopathological factors and nomograms predicting nonsentinel lymph node metastases after neoadjuvant chemotherapy in breast cancer patientsP Gimbergues, C Abrial, X Durando, et al.
Annals of Surgical Oncology|February 16, 2010
Intraoperative imprint cytology examination of sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patientsP Gimbergues, M M Dauplat, X Durando, et al.
Cancer Epidemiology|March 16, 2025
Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational studyJ Passildas, M J Paillard, L Uwer, et al.
International Journal of Cancer|December 10, 2015
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancerJ M Nabholtz, N Chalabi, N Radosevic-Robin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impactJ M Nabholtz, C Abrial, M A Mouret-Reynier, et al.
Pageof 2